NCT01433497View on ClinicalTrials.gov

Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis

PHASE3CompletedINTERVENTIONAL
Enrollment

656

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

September 30, 2019

Study Completion Date

February 29, 2020

Conditions
Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Relapse Free
Interventions
DRUG

Masitinib

DRUG

Placebo

Trial Locations (8)

1431

"St. Ivan Rilski University Multiprofile Hospital for Active Treatment", Sofia

34295

Hôpital de Gui de Chauliac, Montpellier

59020

GHICL hopital ST vincent de Paul, Lille

115100

Centrul Medical Clubul Sănătăţii, Campulung Muscel

D-35033

Universitätsklinikum Gießen und Marburg, Marburg

382 21

"Rehibilitation Center KENTAVROS", Volos

20-362

KO-MED Centra Kliniczne Lublin II, Lublin

08041

Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors

Lead Sponsor

AB Science
All Listed Sponsors
lead

AB Science

INDUSTRY